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Abstract: Mood disorders are among the most prevalent and recurrent forms of psychiatric 
illnesses. In the last decade, there has been increased understanding of the biological basis of 
mood disorders. In fact, novel mechanistic concepts of the neurobiology of unipolar and bipolar 
disorders are evolving based on recent pre-clinical and clinical studies, most of which now 
focus on the role of signal transduction mechanisms in these psychiatric illnesses. Particular 
investigative emphasis has been given to the role of phosphorylating enzymes, which are crucial 
in regulating gene expression and neuronal and synaptic plasticity. Among the most important 
phosphorylating enzyme is protein kinase A (PKA), a component of adenylyl cyclase−cyclic 
adenosine monophosphate (AC−cAMP) signaling system. In this review, we critically and com-
prehensively discuss the role of various components of AC−cAMP signaling in mood disorders, 
with a special focus on PKA, because of the interesting observation that have been made about 
its involvement in unipolar and bipolar disorders. We also discuss the functional signiﬁ  cance of 
the ﬁ  ndings regarding PKA by discussing the role of important PKA substrates, namely, Rap-1, 
cyclicAMP-response element binding protein, and brain-derived neurotrophic factor. These 
studies suggest the interesting possibility that PKA and related signaling molecules may serve 
as important neurobiological factors in mood disorders and may be relevant in target-speciﬁ  c 
therapeutic interventions for these disorders.
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Introduction
Mood disorders are among the most prevalent and recurrent forms of psychiatric 
illnesses. Unipolar depression affects about 17% of the population at some point in life 
(Kessler et al 1994; Hirschfeld 2002). Of these, about 4% of men and 8% of women 
are at a lifetime risk for a severe form of depression, and an additional 20% are at 
risk for milder forms. Major depression is often a chronic and lifelong illness, and 
about 80% of the depressed population experience multiple episodes. Each depressive 
episode greatly increases the risk of future episodes and also lessens responsiveness 
to treatments. About 10% of patients who experience a single or multiple episodes of 
depression can have a manic episode. About 1%–2% of the total population is at risk 
for bipolar disorder (recurrent depressive and manic episodes), and another 2%–3% 
may have milder forms (Spearing 2001; Hirschfeld et al 2002). Both depression and 
bipolar disorders are associated with a high risk of suicide. Among teenagers, bipolar 
patients are at twice the risk to commit suicide as unipolar depressed patients; however, 
the risk of suicide is higher in elderly patients over the age of 60 who are suffering from 
unipolar depression. Therefore, researchers are striving for greater understanding of 
the neurobiology of these disorders that will lead to better treatment and prevention.
Both unipolar and bipolar disorders are complex, and no uniﬁ  ed theory can 
currently satisfactorily explain this complexity. Besides the clinical manifestation, Neuropsychiatric Disease and Treatment 2008:4(1) 162
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there are subtypes of unipolar and bipolar disorders, and 
patients with these subtypes respond differently to vari-
ous treatment approaches. Although depression is a part of 
bipolar disorder, it still is unclear whether the neurobiology 
of unipolar depression is similar to that of the depressive 
state in bipolar disorder.
Earlier studies focused on the role of monoamines in the 
pathophysiology of mood disorders, hypothesizing decreased 
availability of monoamines in the synaptic cleft and 
probably a compensatory increase in monoamine receptors 
(Jans et al 2007). This was substantiated by observations of 
an increased availability of monoamines after treatment with 
antidepressants. These studies provided useful information 
of the involvement of monoamines and monoamine 
receptors in the pathophysiology of mood disorders, but 
they also raised several important questions. For example, 
monoamine depletion does not produce depressive symptoms 
in normal individuals. Also, not every patient responds to 
the antidepressants that modulate monoamines. In addition, 
there is a lag time between starting an antidepressant or 
mood stabilizing drug treatment and responsiveness. It takes 
about 2–4 weeks for these drugs to become fully effective 
and thus the immediate effects on monoamines or receptors 
cannot explain their mechanisms of action. In addition, a 
number of neurotransmitter receptors have been implicated 
in the pathophysiology of mood disorders, and they interact 
with each other in a complex fashion, mostly at the level 
of intracellular signal transduction mechanisms. Most 
neurotransmitter receptors regulate intracellular reactions by 
an indirect mechanism involving an intermediate transducing 
molecule known as guanosine 5’-triphosphate (GTP) binding 
protein, or G protein. Activated G proteins alter the functions 
of many signaling pathway downstream effectors. Most of 
these effectors are enzymes that produce intracellular second 
messengers. The second messengers trigger the signaling 
cascade further downstream and cause a cellular response. It 
is the downstream intracellular signaling mediated by these 
neurotransmitter receptors that co-ordinates the behavior 
of individual cells within the brain in various physiological 
processes.
Emerging evidence indicates that mood disorders are 
associated with altered neuronal plasticity (Duman 2000; 
Duman et al 2000). A number of studies using magnetic 
resonance spectroscopy, anatomical, and morphometric tech-
niques have repeatedly shown that there are structural abnor-
malities in the brains of depressed or bipolar patients (Soares 
and Mann 1997; Rajkowska 2000, 2002). Adaptive responses 
in intracellular molecules, together with the modulation of 
functional responses mediated by the phosphorylation of 
critical proteins, and ultimately gene expression, controlled 
by intracellular signaling cascades, all participate in a major 
way in synaptic and structural plasticity. Given the critical 
importance of intracellular signaling in amplifying, integrat-
ing, and regulating physiological processes and in mediating 
gene expression, over the last decade numerous studies have 
examined the role of signaling molecules in the pathophysiol-
ogy of mood disorders.
One of the major intracellular signaling pathways that 
has been implicated in synaptic and structural plasticity 
is adenylyl cyclase−cyclic adenosine monophosphate 
(AC−cAMP) signaling. Phosphorylation mediated by 
the cAMP signaling pathway can be elicited by various 
physiological ligands in cells and is critically involved in 
cell growth, differentiation, apoptosis, and gene expression 
(Skahegg and Tasken 2000). In this review, we will discuss 
the role of the adenylyl cyclase−cAMP signaling pathway 
in mood disorders in general, including the results of 
investigations of cAMP and adenylyl cyclase, but major 
emphasis will be given for the role of the enzyme protein 
kinase A (PKA), which mediates phosphorylation and, 
therefore, physiological functions in the brain.
Adenylyl cyclase−cAMP signaling 
pathway
A schematic representation of the adenylyl cyclase−cAMP 
signaling pathway is provided in Figure 1. A number of 
neurotransmitter receptors, including serotonergic and 
adrenergic, utilize this pathway to mediate their physiologi-
cal functions. In this signaling pathway, an agonist binding 
to receptors causes the activation of heterotrimeric guanine 
nucleotide binding protein (G proteins), which consist of 
α, β, and γ subunits. The receptor-mediated activation 
of G proteins causes the release of guanine nucleotide 
diphosphate (GDP) from α subunit, allowing GTP to bind 
to and dissociate the α subunit from the βγ subunits. Both 
α and βγ subunits can then modulate activity of effectors, 
including adenylyl cyclase. Activation of adenylyl cyclase 
causes the conversion of ATP to cAMP, which serves as a 
second messenger. cAMP then activates the phosphorylation 
enzyme PKA. Once activated, PKA phosphorylates various 
intracellular proteins and thereby modiﬁ  es hormonal and 
neurotransmitter responses, including receptor downregula-
tion or desensitization, alteration of neurotransmitter release, 
and activation or repression of gene expression (Borrelli 
et al 1992; Spaulding 1993; Nestler and Greengard 1994). 
The negative regulation of cAMP signaling occurs through Neuropsychiatric Disease and Treatment 2008:4(1) 163
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the activation of cAMP-speciﬁ  c phosphodiesterases, which 
convert cAMP to 5’AMP.
Adenylyl cyclase and cAMP 
formation in mood disorders
Since regulation of the intracellular level of a second 
messenger is critical for the transduction of a cellular 
response, many studies have examined cAMP generation 
in mood disorders. The intracellular level of cAMP is 
determined by the rate of its synthesis from ATP by adeny-
lyl cyclase. Most earlier studies utilized peripheral tissues 
to examine levels of cAMP or receptor-mediated cAMP 
formation. For example, it was shown that the baseline level 
of cAMP in plasma, cerebrospinal ﬂ  uid (Belmaker et al 
1980; Post et al 1982; Maj et al 1984), or in leukocytes or 
lymphoblast cell lines (Klysner et al 1987; Kay et al 1993), 
is not altered in various mood states. On the other hand, 
changes in receptor-mediated cAMP formation were found 
in these patients. The inhibition of cAMP formation by 
prostaglandins (PG) has commonly been used as an index 
of imidazoline (I)2-adrenergic receptor responsiveness. 
Using this approach, Wang et al (1974) reported that PGE1-
stimulated cAMP accumulation and norepinephrine (NE) 
inhibition of PGE  1-stimulated cAMP accumulation were not 
changed in platelets of depressed patients. Similar results 
were reported by Murphy et al (1974). On the other hand, 
Siever et al (1984) observed decreased PGE1-stimulated 
cAMP accumulation and the inhibition of this response by 
NE in platelets of depressed patients; and Kanof et al (1986) 
observed that whereas PGE1-stimulated cAMP response was 
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Figure 1 Overview of the adenylyl cyclase–cyclicAMP signaling system. In this signaling pathway, the binding of agonists to receptors leads to the activation of G proteins, which 
in turn activate adenylyl cyclase. In the inactive state the α subunit of G protein is bound to GDP and to βγ subunits. The binding of agonists to receptors causes an interaction 
of receptors with G proteins, which, in turn, releases GDP in exchange with GTP. This leads to generation of α-GTP and a βγ subunits dimer. Both α and βγ subunits can interact 
with effectors. Activation of adenylyl cyclase causes generation of cAMP from ATP.  cAMP binds to the regulatory (R) subunits of tetrameric PKA holoenzymes. The binding of 
cAMP to an R subunit lowers its afﬁ  nity for the C subunit. This causes the release of free catalytic (C) subunits. The C subunit can catalyze reversible protein phosphorylation 
and irreversible phosphorylation of newly synthesized peptides. Phosphorylation of substrates can occur in the cytoplasm or, after translocation of the C subunits, in the nucleus. 
One of the substrates of PKA is transcription factor cyclicAMP response element binding protein CREB, which regulates transcription of many neuronally expressed genes, 
including brain-derived neurotrophic factor (BDNF). The exchange protein activated by cAMP (Epac) is stimulated by cAMP to exchange GDP with GTP on Rap-1. Rap can also 
be regulated by phosphorylation by a C subunit of PKA. Deactivation of PKA is achieved through degradation of cAMP to 5’AMP by cAMP-speciﬁ  c phosphodiesterases.Neuropsychiatric Disease and Treatment 2008:4(1) 164
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signiﬁ  cantly decreased, NE inhibition of PGE1-stimulated 
cAMP formation was not changed in platelets of depressed 
patients (Kanof et al 1988). Thus, studies of the respon-
siveness of α2-adrenergic receptors (ARs) in platelets of 
depressive patients do not consistently show decreased PGE1-
stimulated cAMP response in depressed patients.
Besides α-AR-mediated responsiveness, the functional 
signiﬁ  cance of β-ARs in depression was out by determining 
agonist-stimulated cAMP formation in leukocytes or 
lymphocytes of depressed patients and normal controls 
by our group (Pandey et al 1979) and other investigators 
(Healy et al 1983; Mann et al 1985; Klysner et al 1987; 
Ebstein et al 1988). Pandey et al (1979) reported for the 
ﬁ  rst time that NE-stimulated [3H]cAMP accumulation was 
signiﬁ  cantly lower in leukocytes of depressed or bipolar 
patients; signiﬁ  cantly lower isoproterenol-stimulated cAMP 
accumulation was also observed in these patients. In the 
same year, Extein et al (1979) reported similar ﬁ  ndings in the 
lymphocytes of a mixed group of depressed or manic patients. 
Mann et al (1985) also observed lower isoproterenol-
stimulated cAMP levels in lymphocytes of patients with 
endogenous depression. Ebstein et al (1988) determined 
isoproterenol-, forskolin-, as well as PGE1-stimulated cAMP 
accumulation in lymphocytes of depressed patients and 
observed that the isoproterenol-stimulated cAMP level was 
signiﬁ  cantly decreased in these patients. These investigators 
also observed signiﬁ  cantly lower isoproterenol-stimulated 
cAMP accumulation in depressed nonresponders compared 
with responders. Kanof et al (1989) also observed lower 
isoproterenol-stimulated cAMP accumulation in depressed 
patients. On the other hand, a number of studies suggest the 
opposite changes in cAMP formation in bipolar patients. 
For example, Young et al (1993) reported that forskolin-
stimulated adenylyl cyclase activity is signiﬁ  cantly increased 
in temporal and occipital cortices of bipolar patients 
compared with normal control subjects. Also Kay et al (1993) 
reported that PGE1-stimulated adenylyl cyclase activity was 
signiﬁ  cantly increased in lymphoblast cell lines of bipolar 
patients. Klysner et al (1987) observed increased β2-AR 
responsiveness in manic-depressive patients compared with 
euthymic patients treated with antidepressants.
Adenylyl cyclase exists in multiple forms, each a 
unique gene product (Tang and Gilman 1991), and can be 
grouped into three main classes: 1) Types II, IV, and VII 
are activated synergistically by Gsα and Gβγ subunits; 2) 
Types V and VI are inhibited by Giα and Ca2+; and 3) Types 
VIII, I, and III are activated synergistically by Gsα together 
with Ca2+-calmodulin. Reiach et al (1999) reported that 
immunolabeling of speciﬁ  c types (Type IV) and activity of 
adenylyl cyclase are signiﬁ  cantly decreased in postmortem 
brain of depressed suicide victims compared with normal 
control subjects. Although the signiﬁ  cance of the decrease 
in this speciﬁ  c type of adenylyl cyclase is not clear, nonethe-
less this supports the ﬁ  ndings of decreased cAMP signaling 
in depressed patients. The status of expression of adenylyl 
cyclase subunits in bipolar disorder has not been studied.
Overall these studies show a differential response of 
agonist-induced cAMP formation in response to β2-ARs 
activation. On the one hand, depressed patients show 
decreases in responsiveness of β2-ARs, adenylyl cyclase 
activity, and expression of a speciﬁ  c subtype of adenylyl 
cyclase; bipolar patients, on the other hand, show increased 
forskolin-, PGE1- or β-adrenergic-stimulated adenylyl 
cyclase response. Interestingly, a number of studies show 
that the changes in adenylyl cyclase responsivity are not 
accompanied by consistent changes in β-AR density or 
afﬁ  nity (Mann et al 1985; Berrettini et al 1987; Jeannin-
gros et al 1991), which suggests that post-receptor signal 
transduction mechanisms may be playing an important role 
in mood disorders, albeit in a different manner in unipolar 
versus bipolar disorders.
Protein kinase A (PKA) in mood 
disorders
Since most of the effects of cAMP are mediated by its 
receptor PKA, and since a number of studies suggest that 
PKA is regulated by sustained activation of cAMP (Spaulding 
1993; Francis and Corbin 1999), studying the status of PKA 
can thus provide a direct evidence of altered cAMP signaling. 
In addition, PKA participates directly in many physiological 
functions in the central nervous system, and by phosphorylat-
ing the components of other signaling cascades, it provides 
the means for cross-talk between the AC−cAMP and other 
signaling systems (Beebe 1994; Bornfeldt and Krebs 1999; 
Jordan et al 2000). Therefore, a number of recent studies have 
focused on the role of PKA in mood disorders.
Characteristics of PKA
As shown in Figure 1, PKA is a holoenzyme composed of 
two genetically distinct regulatory (R) and two catalytic 
(C) subunits that form a tetrameric holoenzyme (R2C2). 
In the absence of cAMP, PKA exists as a stable inactive 
tetramer; the catalytic activity of cAMP is suppressed 
when the C subunits form a complex with the R subunits. 
After an increase in intracellular cAMP, the regulatory 
PKA subunits bind to cAMP in a co-operative manner, Neuropsychiatric Disease and Treatment 2008:4(1) 165
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which results in the disassociation of the holoenzyme into 
an R2(cAMP)4 dimer and two monomers of catalytically 
active C kinase. The R subunits remain in the cytoplasm, 
and the free catalytic subunits either translocate into the 
nucleus (Wolf et al 1999) or remain in the cytosol. In both 
locations, PKA C subunits phosphorylate serine and threo-
nine residues of speciﬁ  c substrates (Scott et al 1990). In the 
nucleus, regulation of transcription by PKA is mediated by 
cAMP-responsive nuclear factors, which bind to and regu-
late the expression of genes containing a cAMP-response 
element binding element (CRE) consensus in their promoter 
region. Phosphorylation of the CRE binding protein (CREB) 
modulates its activity. One of the important genes whose 
transcription is regulated by PKA/CREB is brain derived 
neurotrophic factor (BDNF), described later in this review. 
Besides its role in gene transcription, PKA is capable of 
phosphorylating a large number of substrates involved 
in neurotransmitter release; receptor desensitization; cell 
growth, differentiation, survival; and synaptic plasticity 
(Borrelli et al 1992; Nestler and Greengard 1994; Riccio 
et al 1999; Lara et al 2003).
On the basis of the elution proﬁ  le on DEAE exchange 
chromatography, two major forms of PKA have been identi-
ﬁ  ed, ie, Type I and Type II. These two types differ in their 
structure in the regulatory subunits incorporated, termed 
RI or RII, whereas their catalytic subunits are either identi-
cal or very similar. Cloning studies have revealed multiple 
isoforms for each regulatory and catalytic subunit. Two 
RI subunits, termed RIα and RIβ, and two RII subunits, 
termed RIIα and RIIβ, have been identiﬁ  ed. Furthermore, 
three distinct catalytic subunits have been identiﬁ  ed, termed 
Cα, Cβ, and Cγ. These isozymes may form either homo- 
or heterodimers of the R subunits yielding holoenzyme 
complexes of PKA composed of a number of different 
combinations, including RIα2C2, RIβ2C2, RIIα2C2, RIIβ2C2, 
and RIαRIβC2. The presence of multiple C subunits adds 
substantial diversity to the action of PKA. Each regulatory 
and catalytic subunit is a separate gene product and has a 
distinct expression pattern in different tissues (Scott et al 
1987; Clegg and McKnight 1988; Skalhegg and Tasken 
2000). For example, tissue distribution studies suggest that 
RIIβ is predominantly expressed in brain, adrenal, and adi-
pose tissues and is the principal mediator of cAMP activity 
in the mammalian CNS (Sarkar et al 1984), whereas Cβ 
is expressed primarily in the brain (Uhler et al 1986). On 
the other hand, whereas Cα is ubiquitously expressed. Cγ 
is present only in testis. We will discuss all those C and R 
subunits which are present in brain.
PKA in bipolar disorder
The Warsh group provided the ﬁ  rst evidence that PKA 
may be altered in bipolar disorder. They found signiﬁ  cantly 
decreased [3H]cAMP binding to regulatory subunits in the 
cytosolic but not in the membrane fractions of frontal, tem-
poral, and occipital cortices, cerebellum, and thalamus of 
bipolar patients (Rahman et al 1997). They further observed 
greater basal and cAMP-stimulated PKA activity, and lower 
EC50 values for cAMP stimulation of PKA activity, in the 
temporal cortex of bipolar patients (Fields et al 1999).
Clinical studies performed in blood cells also provide 
evidence of abnormalities in PKA in bipolar patients. For 
example, Karege et al (2002a; 2004) reported that PKA activ-
ity is signiﬁ  cantly greater in the cytosolic fraction of cultured 
lymphoblasts from euthymic bipolar patients compared with 
normal controls. In addition, they found that [3H]cAMP bind-
ing is decreased in the cytosolic fraction of lymphoblasts of 
bipolar patients. The results of these studies are similar to the 
ﬁ  ndings in postmortem brain of bipolar patients.
In postmortem brain of bipolar patients, Chang et al 
(2003a) found that the levels of cytosolic Cα and RIIβ in 
temporal cortex were signiﬁ  cantly higher in bipolar patients. 
This indicates that the increased PKA activity in postmortem 
brain and in platelets of bipolar patients could be due to 
increased levels of Cα. The authors argued that an increase 
in RIIβ level may be associated with an increase in PKA II 
and a decrease in PKA I holoenzyme levels. PKA RII has a 
much lower afﬁ  nity for cAMP than the type I PKA holoen-
zyme. Such a putative shift in PKA I and PKA II holoenzyme 
levels could have accounted for the decreased [3H]cAMP 
binding found in bipolar patients (Chang et al 2003a). Perez 
et al (1999) also reported increased PKA catalytic subunits 
in bipolar patients, although they did not examine whether 
this increase was in α or β subunits of PKA. Using the same 
brain tissues, Chang et al (2003b) did not ﬁ  nd any signiﬁ  cant 
differences in mRNA levels of these C and R subunits of 
PKA in bipolar patients, suggesting that a post-translational 
mechanism is responsible for the changes in protein levels 
of RIIβ and Cα subunits.
PKA in unipolar disorder
A number of studies in peripheral tissues of depressed 
patients suggest abnormalities in the cAMP signaling path-
way at the level of PKA. For example, Shelton et al (1996) 
and Manier et al (1996) reported signiﬁ  cantly decreased 
β-adrenergic receptor-stimulated PKA activity in the presence 
of cAMP in ﬁ  broblasts of depressed patients. Shelton et al 
(1999) later conﬁ  rmed that β-adrenergic receptor-stimulated Neuropsychiatric Disease and Treatment 2008:4(1) 166
Dwivedi and Pandey
PKA activity was decreased only in melancholic depressed 
patients but not in other depressive subtypes. More recently, 
Akin et al (2005) reported reduced PKA activity along with 
reduced expression of PKA RIIα, Cα, and Cβ subunits in 
ﬁ  broblasts of melancholic depressed subjects as compared 
with nonmelancholic and normal control subjects. Overall 
these studies in peripheral tissues demonstrate decreased 
activation of PKA in depressed patients, which could be 
associated speciﬁ  cally with melancholic subtype.
In a comprehensive study, we examined whether PKA 
is altered in postmortem brain of suicide subjects by com-
paring suicide subjects with and without major depression 
(Dwivedi et al 2002a). We observed that [3H]cAMP binding 
and basal and cAMP-stimulated PKA activity were sig-
niﬁ  cantly decreased in prefrontal cortex of suicide victims. 
The extent of the decrease in cAMP-stimulated PKA activ-
ity was greater than that of the endogenous PKA activity. 
Interestingly, we found signiﬁ  cant changes only in those 
suicide victims who had major depression but not in those 
who had other mental disorders. We recently conﬁ  rmed this 
ﬁ  nding in a large population of depressed suicide victims 
obtained from another cohort (Dwivedi et al 2004a). We 
further examined whether the decreases in PKA regulatory 
and catalytic activities are related to altered expression of 
speciﬁ  c C and/or R subunits. Interestingly, we observed that 
protein levels of only PKA RIIβ and Cβ were signiﬁ  cantly 
lower in prefrontal cortex of depressed suicide subjects, 
without any changes in protein levels of the other regulatory 
or catalytic subunits. These decreases were associated with 
decreases in their respective mRNA levels. Our results thus 
suggest that the decreases in [3H]cAMP binding and PKA 
activity could be due to decreases in the expression of RIIβ 
and Cβ, respectively. Odagaki et al (2001) found similar 
results in prefrontal cortex of depressed patients. In a clini-
cal population, Perez et al (2001) studied the expression of 
PKA R and C subunits and found that the level of regulatory 
subunits of type II PKA was signiﬁ  cantly lower in platelets 
of untreated depressed patients compared with euthymic 
patients or normal controls.
Overall, studies of PKA in unipolar and bipolar patients 
suggest that whereas cAMP binding is decreased in both 
bipolar and depressed patients, PKA activity is increased in 
bipolar patients and decreased in depressed patients. In addi-
tion, the expression of RIIβ is increased in bipolar patients 
and decreased in depressed patients. On the other hand, 
whereas the Cβ subunit is decreased in depressed patients, 
the level of Cα is increased in bipolar patients. Thus, it 
appears that PKA is differentially regulated in depressed 
versus bipolar patients. The postmortem brain studies did 
not differentiate between melancholic and nonmelancholic 
subtypes, therefore, it is difﬁ  cult to state that the changes in 
PKA in depressed subjects are speciﬁ  c to one subtypes as sug-
gested in studies of peripheral tissues of depressed subjects. 
Further studies are required to conﬁ  rm these ﬁ  ndings.
Hypothalamic-pituitary-adrenal axis 
(HPA) and PKA
Effect of Stress on PKA
Stress is known to cause changes in the hypothalamic-
pituitary-adrenal (HPA) axis in both humans as well as in 
nonhuman models. Stress or a hyperactive HPA axis is a 
well-known phenomenon in depression. It is, therefore, of 
interest to examine whether changes in PKA are related 
to stress. In a detailed study, we examined the effect of 
glucocorticoids after bilateral adrenalectomy and supple-
mentation with exogenous glucocorticoid, as well as the 
effect of endogenous glucocorticoids, on various measures 
of PKA in rat brain (Dwivedi et al 2000). For this, rats were 
injected with various doses of corticosterone at different 
time intervals, and in a separate experiment, adrenalecto-
mies were performed on rats who were then injected with 
various doses of corticosterone. We observed that 1 day of 
corticosterone treatment had no signiﬁ  cant effect, but 4 days 
of corticosterone treatment decreased [3H]cAMP binding to 
the regulatory subunit of PKA and PKA catalytic activity in 
the rat cortex and hippocampus. These changes were much 
more profound after 14 days of corticosterone. These effects 
were also dose dependent. The higher dose of corticosterone 
was much more effective in causing changes in PKA than 
the lower dose. Adrenalectomy produced the direct oppo-
site results to those of corticosterone treatment, increasing 
[3H]cAMP binding and PKA activity in both cortex and 
hippocampus in a time-dependent manner. These changes 
were reversed by corticosterone treatment in a dose depen-
dent manner. The higher dose of corticosterone completely 
reversed the changes in PKA after adrenalectomy (Dwivedi 
et al 2000). A very interesting observation was noted when 
we examined the expression levels of PKA regulatory and 
catalytic subunits. We found that the mRNA and protein 
expressions of RIα, RIIβ, and Cβ isoforms were signiﬁ  cantly 
decreased in cortex and hippocampus after corticosterone 
treatment. Removal of adrenal glands increased the expres-
sion of these subunits, and corticosterone treatment of 
adrenalectomized rats reversed the adrenalectomy-induced 
changes in PKA RIα, RIIβ, and Cβ subunits (Dwivedi 
et al 2000). These changes were very similar to those we Neuropsychiatric Disease and Treatment 2008:4(1) 167
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observed in depressed suicide subjects. Our studies thus 
suggest that the expression of speciﬁ  c isoforms of PKA 
regulatory and catalytic subunits is under the regulation of 
glucocorticoids and that stress may be playing an important 
role in such changes.
Effect of learned helpless behavior
on PKA
Since the ability to cope with stress is critical at the human 
level, parallel studies of the effects of uncontrollable stress 
have been performed in animals, with the results of proac-
tive interference with the acquisition of escape/avoidance 
responding (Seligman and Maier 1967). This phenomenon 
is termed learned helplessness (LH) and has been used 
extensively as an animal model of stress-induced behavioral 
depression (Petty and Sherman, 1979; Sherman et al 1982). 
To further examine whether there were alterations in PKA in 
LH behavior, we studied similar paradigms in the brain of LH 
rats as we studied in the brain of suicide subjects. We found 
very similar changes in PKA, such that [3H]cAMP binding 
and PKA activity were signiﬁ  cantly decreased along with 
selectively decreased expression of only RIIβ and Cβ sub-
units (Dwivedi et al 2004b), as we had observed in depressed 
suicide subjects. These changes were well correlated with 
the stress-induced behavioral paradigms. For example, LH 
behavior dissipated 4 days after the induction of LH. At the 
same time, in these animals, the changes in PKA also reverted 
to the normal level, which suggests that the changes in PKA 
were speciﬁ  c to stress-induced behavioral depression. Inter-
estingly, very recently, Rao et al (2007a) reported that CBZ 
treatment signiﬁ  cantly decreased cAMP-dependent PKA 
activity, but not basal PKA activity, compared with control 
values On the other hand, animal model of depression show 
that PKA activity is increased in frontal cortex of rats (Rao 
et al 2007b). These studies further strengthen the hypothesis 
that bipolar disorder could be associated with increased PKA, 
which may be reversed by mood stabilizing drugs.
Mechanistic and functional aspects of PKA changes
The mechanisms responsible for the selectively altered 
expression of PKA subunits in bipolar or depressed patients 
are not clear at the present time. From Chang’s study (Chang 
et al 2003b) it is clear that the alterations in RIIβ and Cα pro-
tein levels in postmortem brain of bipolar patients are due to 
changes at the post-translational level. In depressed patients, 
however, we found that mRNA levels of RIIβ and Cβ were 
decreased (Dwivedi et al 2004a). It has been demonstrated in 
rat Sertoli cells, that activation of the cAMP pathway stimulates 
mRNA levels of RIα, RIIα, Cα, and RIIβ, the increase in 
RIIβ being the greatest (Oyen et al 1988; Landmark et al 
1993). However, prolonged stimulation with cAMP results 
in a decrease in RIIβ mRNA (Oyen et al 1988). In depressed 
patients, it has been shown that the expression of stimulatory 
G protein (GSα) is increased and of inhibitory G protein (Giα) 
is decreased (Pachecco et al 1996; Dwivedi 2002b), which 
suggests greater stimulation of the cAMP pathway. It is quite 
possible that this sustained stimulation may cause an adaptive 
change in expression of the RIIβ subunit. Another possible 
explanation of the reduced expression of the RII β subunit 
could be related to protein kinase C (PKC), a phosphorylat-
ing enzyme in the phosphoinositide signaling pathway. It has 
been shown that activation of PKC inhibits cAMP induction 
of RIIβ mRNA and that this inhibition persists even after 
PKC downregulation (Tasken et al 1992). The explanation 
of the selective decrease in the Cβ subunit is more complex. 
It has been shown that regulatory subunits associate with 
catalytic subunits and protect the catalytic subunits from 
degradation by proteolytic enzymes (Steinberg and Agard 
1981). Furthermore, in brain tissues of RIIβ-mutant mice, 
there is a profound decrease in Cα and Cβ subunit levels due 
to increased degradation Brandon et al (1998). However, in 
postmortem brain of depressed subjects, expression of only 
the Cβ subunit was decreased, and this decrease was pres-
ent at both the transcriptional and the translational levels, 
eliminating the possibility of any degradation. It appears 
that additional factors or mechanisms may be involved in the 
regulation of the Cβ gene in postmortem brain of depressed 
suicide subjects. Irrespective of the mechanisms involved, 
the above-mentioned studies clearly indicate that speciﬁ  c 
catalytic and regulatory subunits of PKA are differentially 
regulated in unipolar and bipolar disorders.
As mentioned earlier, at the functional level, PKA is 
involved in myriads of physiological functions in the brain, 
including neurotransmitter synthesis and release, gene 
expression, synaptic plasticity, memory, and cell growth and 
differentiation. Furthermore, PKA participates in neurite out-
growth (Song and Poo 1999), neuronal differentiation (Liesi 
et al 1983), and cell survival (Rydel and Greene 1988; Li et al 
2000). The major mechanism of PKA-mediated function is 
through the phosphorylation of speciﬁ  c substrates, which 
include CREB, nuclear receptors, and high mobility group-
containing proteins, thus inﬂ  uencing their dimerization or 
DNA binding properties (Fimia and Sassone-Corsi 2001). 
Any abnormality in the expression or catalytic activation state 
of PKA would alter the functional capacity of the substrates 
that are activated in response to PKA activation. Some of Neuropsychiatric Disease and Treatment 2008:4(1) 168
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the substrates whose functions are altered in mood disorders 
are discussed in the next sections.
Another important aspect of PKA is its involvement in 
the cross-talk between different signaling mechanisms. For 
example, PKA interacts at various levels with other signal-
ing pathways, including inactivation of phospholipase C 
(PLC)β (Liu and Simon 1996); phosphorylation of inositol 
1,4,5-trisphosphate (IP3) receptors, thereby modulating Ca2+ 
inﬂ  ux (Bugrim 1999); phosphorylation of G proteins, with a 
consequent decrease in PI hydrolysis and Ca2+ release (Wen 
et al 1992); and phosphorylation of calcium-calmodulin 
kinase (Matsushita and Nairn 1999).Through these actions 
PKA also profoundly affects physiological functions medi-
ated by other signaling pathways.
The functions of each speciﬁ  c catalytic and regulatory 
subunit of PKA are not clear; however, Ludvig et al (1990) 
showed that RIIβ immunolabeling is associated with post-
synaptic structures, suggesting that this subunit is involved 
in several post-synaptic neuronal functions. Also a few stud-
ies indicate that each catalytic and regulatory subunit has 
distinct functions in the CNS. For example, Constantinescu 
et al (2002) reported that in NG108-15 cells, which contain 
type I PKA (CαRIβ) primarily in cytosol and type II PKA 
(CαRIIβ) in the particulate and nuclear fractions, forskolin- 
or ethanol-stimulated activation of CREB and gene activa-
tion are differentially regulated by the two different types of 
PKAs. Exposure of these cells to ethanol or forskolin caused 
translocation of only Cα, but not Cβ, to the nucleus. They 
have proposed that Type II PKA is responsible for the induc-
tion of CREB. Interestingly, it has been shown that RIIβ can 
bind to and activate transcription via CRE (Srivastava et al 
1998). Binding of RIIβ to CRE is enhanced by cAMP, and 
mutant mice lacking the autophosphorylation site exhibit 
reduced capacity to bind CRE (Srivastava et al 1998). On the 
other hand, Type I PKA is activated in the cytoplasm, and 
activates other transcription cofactors, whcih interact with 
phosphorylated CREB to induce gene transcription. Further 
evidence is derived from a study showing that Type I PKA 
controls cell growth whereas Type II PKA participates in 
growth arrest and induction of apoptosis (Cho-Chung 1990). 
Also, many studies have demonstrated that RIIβ and Cβ sub-
units may be speciﬁ  cally involved in neuronal and behavioral 
functions. For example, RIIβ-mutant mice exhibit defective 
motor behavior (Brandon 1998) and Cβ-mutant mice show 
impaired hippocampal plasticity (Qi et al 1996). Targeted 
disruption of the RIβ subunit gene results in mice that exhibit 
defects in long-term depression and depolarization, which 
suggests a deﬁ  cit in a learning-related form of synaptic 
plasticity (Brandon et al 1998). It has also been shown that 
RIβ deﬁ  ciency produces selective defects in mossy ﬁ  ber 
long-term potentiation (Brandon et al 1998).
Whether the observed selective abnormalities in expres-
sion of catalytic and regulatory subunits pertain to a speciﬁ  c 
disease state, such as unipolar or bipolar disorder, is not 
clear at the present time. However, given the signiﬁ  cance of 
PKA in many biological actions in the brain, together with 
emerging studies demonstrating speciﬁ  c roles for its regula-
tory and catalytic subunits in physiological and behavioral 
manifestations, the observations of differential regulatory 
and catalytic activities, along with differential selective 
expression of selective regulatory and catalytic subunits, in 
mood disorder patients suggest that these abnormalities in 
PKA may be of critical importance in the pathophysiology 
of mood disorders.
Target substrates of PKA: Role
in mood disorders
Rap-1 in mood disorders
Rap-1 is a member of the Ras family of small guanine nucleo-
tide triphosphates with the highest homology to Ras and is 
highly expressed in the CNS (Kitayama et al 1989; Drugan 
et al 2000; Bos et al 2001). Rap-1 has been shown to be 
activated through the stimulation of various transmembrane 
receptors, including receptor tyrosine kinases, G protein-
coupled receptors, cytokine receptors, and cell-adhesion 
molecules (Hattori and Minato 2003). A number of studies 
suggest that Rap-1 is activated directly by PKA or indirectly 
by cAMP through Epac (cAMP-regulated guanine nucleotide 
exchange factor) (de Rooij et al 1998; Bos et al 2001; Berruti 
2003) and thereby modulates various pathways, including the 
cell survival extracellular signal-regulated kinase (ERK) and 
the phosphoinositide (PI) 3-kinase pathways. This leads to the 
modulation of physiological functions, such as cell prolifera-
tion, differentiation, adhesion, and neurite outgrowth.
To examine the functional response of altered cAMP, 
initially, Perez et al (1995) and Zanardi et al (1997) studied 
cAMP-stimulated phosphorylation of a PKA substrate in 
depressed or bipolar patients and found that the cAMP-
stimulated phosphorylation of a 22-kDa protein (which was 
conﬁ  rmed as Rap-1) was increased in platelets of euthymic 
bipolar patients. Recently, Perez et al (2000) found that 
cAMP-mediated endogenous phosphorylation of Rap-1 
was signiﬁ  cantly increased, along with an increase in level 
of Rap-1, in platelets of euthymic bipolar patients. In another 
study, Perez et al (1999) reported that phosphorylation 
of Rap-1 was signiﬁ  cantly increased in euthymic, depressed, Neuropsychiatric Disease and Treatment 2008:4(1) 169
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or manic patients. On the other hand, they found that the level 
of Rap-1 was signiﬁ  cantly lower in platelets of depressed 
patients (Perez et al 2001). Recently, we investigated Rap-1 
in postmortem brain of depressed suicide subjects and found 
that Rap-1 activation was signiﬁ  cantly reduced in prefrontal 
cortex and hippocampus of these subjects. This was associ-
ated with signiﬁ  cant reductions in Rap-1 mRNA and protein 
levels in these brain areas (Dwivedi et al 2006). These studies 
indicate differences in activation and expression in Rap-1 
in unipolar versus bipolar disorders. The ﬁ  ndings of altered 
Rap-1 in depressed or bipolar patients not only provide the 
functional link to altered PKA but also indicate that abnor-
malities in Rap-1 may be crucial in the pathophysiology of 
mood disorders.
Transcription factor CREB in mood disorders
The functional signiﬁ  cance of various signal transduction 
mechanisms depends upon the activation/repression of 
transcription factors that regulate the expression of genes 
involved in physiological functions. One such transcrip-
tion factor is CREB, whose activity is regulated by PKA. 
CREB is a member of the basic leucine zipper subfamily 
of transcription factors (Borrelli et al 1992). Phosphoryla-
tion of CREB at serine 133 leads to its dimerization and 
activation by binding to the promoter region of target genes 
known as cAMP-response elements (CREs) at the consensus 
motif 5′TGACGTCA3′, which is found in many neuronally 
expressed genes (Montiminy et al 1990). It has been shown 
that CREB can bind to CRE even in the unphosphorylated 
form; however, it does not stimulate transcription unless it is 
phosphorylated at the serine 133 residue. CREB phosphoryla-
tion matches very well with the stimulation of transcription 
of CRE-containing genes. After serine 133 phosphorylation 
by PKA, CREB binds to the transcriptional co-activator 
CREB binding protein (CBP), which leads to stimulation 
of the transcription of many cAMP-responsive genes that 
are involved in several aspects of neuronal functioning, 
including the excitation of nerve cells (Moore et al 1996; 
Marshall and Dragunow 2000), central nervous sytem (CNS) 
development, long-term synaptic plasticity (Silva et al 1998), 
and cell survival.
A number of direct and indirect studies demonstrate 
that CREB could be involved in mood disorders (reviewed 
by Sulser et al 2002). Studies in rodents demonstrate that 
overexpression of CREB in hippocampus causes antidepres-
sant-like effects in forced swim stressed or learned helpless 
rats (Chen et al 2001). On the other hand, in the temporal 
cortex of depressed patients, Dowlatshahi et al (1998) 
reported decreased CREB immunoreactivity. Yamada et al 
(2003) examined the level of CREB and of its active form, 
phospho-CREB, in orbitofrontal cortex of antidepressant-
free patients with major depression. They found that both 
CREB and phospho-CREB were signiﬁ  cantly decreased in 
depressed subjects. In another study, Manier et al (2000) 
found that the isoproterenol-stimulated increase in phospho-
CREB was signiﬁ  cantly decreased in ﬁ  broblasts of depressed 
patients. Akin et al (2005) recently reported decreased phos-
pho-CREB in ﬁ  broblasts of depressed subjects and showed 
that this decrease is associated with the melancholic subtype. 
In a postmortem brain study, we demonstrated that expres-
sion and functional characteristics of CREB were decreased 
in prefrontal cortex and hippocampus of a group of suicide 
subjects that included depressed suicide subjects (Dwivedi 
et al 2003a) A role for CREB in depression is further sup-
ported by a recent study demonstrating a linkage of CREB 
with major depression. In this study Zubenko et al (2002) 
performed a linkage analysis of six polymorphic markers 
located in a 15 cM region of chromosome 2q33-35 and uni-
polar depression. They found signiﬁ  cant linkage of unipolar 
depression to a 451 Kb region of 2q33-34, which contains 
the CREB1 gene. This suggests that the CREB1 gene may be 
an attractive candidate for a susceptibility gene for unipolar 
depression. These described studies thus indicate decreased 
expression/functional response of CREB in depression.
Many different classes of antidepressants upregulate 
CREB expression in rat hippocampus (Nibuya et al 1996), 
which suggests that CREB participates in the mechanism 
of action of antidepressants. Recently, Koch et al (2002) 
investigated phosphorylation of CREB in T-lymphocytes of 
depressed patients before and after antidepressant treatment. 
They found that responders showed a signiﬁ  cant increase in 
phosphorylation of CREB compared with nonresponders, 
suggesting that CREB may be a molecular state marker 
for antidepressant response. Recently, Thome et al (2000) 
studied the functional relevance of increased CREB by anti-
depressants, and observed that in transgenic mice containing 
the CRE-Lac Z reporter, activation of the CRE site led to 
increased CRE-mediated gene transcription.
In contrast to what occurs with antidepressants, Stewart 
et al (2001) found a lower CREB level in temporal cortex 
of bipolar patients treated with mood stabilizing drugs. In 
rat cortex and hippocampus, similar ﬁ  ndings were noted by 
Chen et al (1999), who reported that lithium, but not valpro-
ate, decreased the level of phospho-CREB. An in vitro study 
also suggested that lithium decreases cAMP-dependent 
CREB phosphorylation and DNA binding activity in Neuropsychiatric Disease and Treatment 2008:4(1) 170
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neuroblastoma cells (Wang et al 1999). These studies thus 
suggest that mood stabilizing drugs and antidepressants 
behave differently in regulating CREB. Whether this mean 
that CREB expression is increased in bipolar patients is not 
clear at the present time, however; these studies do point 
in this direction.
BDNF in mood disorders
Among the epigenetic factors that may inﬂ  uence the devel-
opment and survival of neurons in the CNS are neurotroph-
ins. The most important and widely distributed member 
of the neurotrophin family in the brain is BDNF. It has 
been shown that PKA/CREB activation increases BDNF 
transcription through a Ca2/CRE within exon III of BDNF 
(Finkbeiner 2000). BDNF-mediated activation of its cog-
nate receptor, tyrosine receptor kinase (Trk) B, inﬂ  uences 
neurite outgrowth, phenotypic maturation, morphological 
plasticity, and synthesis of proteins for differentiated func-
tioning of neurons and synaptic functioning (Huang and 
Reichardt 2001). Several studies suggest that BDNF is also 
involved in nerve regeneration, structural integrity, and 
maintenance of neuronal plasticity in the adult brain, includ-
ing activity-dependent regulation of synaptic activity, and in 
neurotransmitter synthesis (Thoenen 1995). A pathological 
alteration of the neurotrophic factor system thus may not 
only lead to altered neural maintenance and regeneration, 
and therefore structural abnormalities in the brain, but also to 
reduced neural plasticity. The result could be an impairment 
of an individual’s ability to adapt to crisis situations.
Emerging studies suggest that mood disorders and stress 
may both be associated with structural abnormalities in the 
brain. For example, patients with affective disorders show 
reductions in hippocampal volume, in density and size of 
cortical neurons in the dorsolateral PFC and orbitofrontal 
cortex, and in density of nonpyramidal neurons. There is 
also a layer-speciﬁ  c reduction in interneurons in the ante-
rior cingulate cortex and in nonpyramidal neurons in the 
hippocampal formation, and a marked decrease in glial 
cell number and density in PFC of mood disorder patients 
(Rajkowska 2000; Benes et al 2001; Miguel-Hidalgo et al 
2002). Similarly, several studies show that stress or gluco-
corticoid administration causes neuronal atrophy (Sapolsky 
1996; Brown et al 1999; McEwen 1999), a decrease in the 
number or length of apical dendrites (Woolley et al 1990; 
Watanabe et al 1992), and even loss of hippocampal neu-
rons (Sapolsky 2000). Among the epigenetic factors that 
may inﬂ  uence the development and survival of neurons in 
the CNS are neurotrophins. The most important and widely 
distributed member of the neurotrophin family in the brain 
is BDNF. BDNF-mediated activation of tyrosine receptor 
kinase (Trk) B inﬂ  uences neurite outgrowth, phenotypic 
maturation, morphological plasticity, and synthesis of pro-
teins for differentiated functioning of neurons and synaptic 
functioning (Huang and Reichardt 2001). Recent studies 
suggest that BDNF is also involved in nerve regeneration, 
structural integrity, and maintenance of neuronal plasticity 
in adult brain, including activity-dependent regulation of 
synaptic activity, and in neurotransmitter synthesis (Huang 
and Reichardt 2001; Thoenen 1995). A pathological altera-
tion of the neurotrophic factor system thus may not only 
lead to altered neural maintenance and regeneration, and 
therefore structural abnormalities in the brain, but also to 
reduced neural plasticity. The results could be impairment of 
an individual’s ability to adapt to crisis situations.
BDNF in unipolar disorder
There is a growing body of evidence that demonstrates the 
involvement of BDNF in unipolar disorder. For example, 
Siuciak et al (1996) studied the behavioral effects of midbrain 
infusion of BDNF in rats. They found that rats who received 
BDNF showed greatly reduced learned helpless behavior 
compared with rats who were given saline. Shirayama et al 
(2002) also reported that bilateral infusion of BDNF into the 
dentate gyrus of rats produced an antidepressant-like effect 
in both learned-helpless and forced-swim-test models of 
depression. Further evidence of the role of BDNF in depres-
sion comes from studies of BDNF expression in rat brain 
after different types of stresses. Immobilization stress and 
glucocorticoids signiﬁ  cantly decrease BDNF expression in 
limbic areas (Barbany and Persson 1992; Nibuya et al 1995; 
Smith et al 1995a, 1995b; Duman et al 1997; Ueyama et al 
1997). Chronic treatment with antidepressants prevents the 
stress-induced lowering of BDNF (Nibuya et al 1995; Duman 
2002). More direct evidence is derived from studies show-
ing that serum BDNF levels were signiﬁ  cantly decreased in 
drug-free depressed patients and were negatively correlated 
with Montgomery-Asberg-Depression Rating Scale scores 
(Karege et al 2002b). Recently, Shimizu et al (2003) reported 
that the serum level of BDNF was signiﬁ  cantly decreased in 
antidepressant-free depressed patients compared with those 
medicated with antidepressants or normal controls. They 
also reported that the serum BDNF level was negatively 
correlated with HDRS scores. More recently, we observed 
that expression of BDNF and of the active form of TrkB, 
ie, full-length TrkB, is signiﬁ  cantly decreased in prefrontal 
cortex and hippocampus of depressed and nondepressed Neuropsychiatric Disease and Treatment 2008:4(1) 171
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suicide subjects (Dwivedi et al 2003b). At the genetic level, 
Sen et al (2003) has reported that the val allele of the BDNF 
val66met polymorphism is associated with neuroticism, a 
heritable risk factor for depression, further emphasizing the 
role of BDNF in depression.
Other evidence of the role of BDNF in depression comes 
from studies suggesting that BDNF is a target of antidepres-
sants. For example, chronic administration of several classes 
of antidepressants or electroconvulsive shock upregulates the 
expression of BDNF in rat hippocampus (Smith et al 1995b; 
Nibuya et al 1995). Electroconvulsive shock also increases 
the expression of TrkB in rat hippocampus and blocks the 
downregulation of BDNF in response to restraint-induced 
stress (Nibuya et al 1995; Lindeforts et al 1995). A consecu-
tive 10-day daily exposure to ECS also increases the expres-
sion of BDNF, not only in hippocampus, but also in parietal 
cortex, entorhinal cortex, frontal cortex, neostriatum, and 
septum (Altar et al 2003). Pretreatment with antidepressants 
blocks the stress-induced downregulation of BDNF in hip-
pocampus (Lindeforts et al 1995). A postmortem brain study 
of depressed subjects who were being treated with antidepres-
sants at the time of death also suggests an increase in the level 
of BDNF in hippocampal regions (Chen et al 2001).
BDNF in bipolar disorder
BDNF may also play an important role in the pathophysi-
ology of bipolar disorder. For example, chronic lithium 
or valproate treatment of rats increases the expression of 
BDNF in hippocampus and temporal and frontal cortices 
(Fukumoto et al 2001). A number of genetic studies in 
humans indicate a linkage of BDNF to bipolar disorder. 
Chromosome 11p13-14 is a putative locus for the genes 
responsible for the development of bipolar disorder. The 
BDNF gene is located in this region of the chromosome. 
Recently, family-based association studies for the dinucleo-
tide repeat polymorphism at position -1040 bp showed that 
allele A3 was preferentially transmitted to the affected 
individuals. The results of the val66met single-nucleotide 
polymorphisms (SNP) showed a signiﬁ  cant association 
for allele G. Transmission/disequilibrium test haplotype 
analysis showed a signiﬁ  cant result for the G-allele combi-
nation, which suggests that a DNA varient in the vicinity of 
the BDNF locus confers susceptibility to bipolar disorder 
(Neves-Pereira et al 2002). Sklar et al (2002) studied the 
association between 76 candidate genes and bipolar disorder 
by genotyping 90 SNPs in these genes and identiﬁ  ed BDNF 
as a potential risk allele for bipolar disorder; although Nakata 
et al (2003) found no association for two polymorphisms 
(-1360C > T and 196G > A) in a Japanese population with 
bipolar disorder. Very recently, Tsai (2004) suggested the 
possibility that BDNF overactivity may be associated with 
the manic state on the basis of studies showing: 1) there is 
a positive association between genetic polymorphism of 
BDNF and bipolar disorder, 2) agents that induce mania 
increase BDNF (Peet and Peters 1995; Vollenweider et al 
1998; Meredith et al 2002), 3) atypical antipsychotics, 
often used for the treatment of mania, decrease the level of 
BDNF in frontal and occipital cortices, and hippocampus 
(Angelucci et al, 2000), and 4) there is increased mossy 
ﬁ  ber staining in the supragranular layer in bipolar patients, 
which is associated with BDNF action. Further studies are 
required to explore such an interesting idea.
Conclusion
In this review we have critically discussed the ﬁ  ndings per-
taining to various components of adenyly cyclase−cAMP 
signaling relevant to mood disorders. We have briefly 
included studies pertaining to cAMP formation and adenylyl 
cyclase, however; given the importance of PKA in mediat-
ing crucial physiological functions in the brain, especially 
emphasized is the role of this phosphorylating enzyme in 
mood disorders (Figure 2). Although not consistently, the 
majority of studies suggest that the changes in agonist-
stimulated cAMP formation and in catalytic activation of 
adenylyl cyclase are direct opposites in unipolar versus 
bipolar states, such that cAMP formation and adenylyl 
cyclase activity are decreased in unipolar and increased 
in bipolar disorder. The most consistent ﬁ  ndings were 
observed in PKA, and signiﬁ  cant conclusions can be drawn 
from these ﬁ  ndings. For example, bipolar disorder patients 
show increased PKA catalytic activity, which is associated 
with selectively increased expression of catalytic (Cα) and 
regulatory (RIIβ) subunits. In contrast, unipolar depression is 
associated with decreased PKA activity and decrease expres-
sion of catalytic Cβ and regulatory RII β subunits. These 
observations have been further substantiated by studies in 
rodents which show that corticosterone administration or 
induction of learned helplessness behavior causes similar 
changes in PKA as were found in postmortem brain of 
depressed subjects. The opposite ﬁ  ndings involving cAMP 
formation and adenylyl cyclase and PKA activities in unipo-
lar and bipolar disorders are quite important, and the ﬁ  ndings 
of the differential regulation of PKA C and R subunits in 
these two disorders are especially intriguing. Whether these 
particular PKA subunits are involved in speciﬁ  c behavioral 
and clinical manifestations, remains to be elucidated.Neuropsychiatric Disease and Treatment 2008:4(1) 172
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In addition, interesting ﬁ  ndings about the substrates for 
PKA, namely, Rap-1, CREB, and BDNF, have emerged. For 
example, changes in Rap-1 also appear to be the opposite in 
unipolar and bipolar disorders, as has been for the changes 
in PKA. Similarly, an intriguing hypothesis has been put 
forward suggesting an induction of BDNF expression in the 
manic phase but reduction in its expression in the depressed 
phase. A systematic study in a large population of mood 
disorder patients is required to confirm these findings. 
Overall, in view of the current ﬁ  ndings, a novel concept of 
the neurobiology of mood disorders is evolving in which 
disruptions in PKA/CREB/Rap-1/BDNF signaling could be 
seen as important biological risk factors that may be useful in 
delineating the etiology of these two disorders and eventually 
result in site-speciﬁ  c therapeutic interventions.
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